natgillin/translations-raw huggingface dataset:
The vaccine composition of claim 1 wherein the high HLB non-ionic hydrophilic surfactant is selected from the group consisting of ethoxylated fatty acid monoesters of sorbitan, ethoxylated fatty alcohols, ethoxylated fatty acids, non-ionic block-copolymer, and combinations thereof, and wherein the ethoxylated monoester of sorbitan is selected from the group consisting of ethoxylated sorbitan monolaurate, ethoxylated sorbitan monopalmitate, ethoxylated sorbitan monostearate, ethoxylated sorbitan monooleate, and combinations thereof. 
Sastav cjepiva prema zahtjevu 1, naznačen time, da je neionski hidrofilni tenzid visoke HLB-vrijednosti odabran iz skupine koju čine etoksilirani monoesteri masne kiseline od sorbitana, etoksilirani masni alkoholi, etoksilirane masne kiseline, neionski blok-kopolimer i njihove kombinacije, te time, da je etoksilirani monoester od sorbitana, odabran iz skupine koju čine etoksilirani sorbitan-monolaurat, etoksilirani sorbitan-monopalmitat, etoksilirani sorbitan-monostearat, etoksilirani sorbitan-monooleat i njihove kombinacije.
Preferably both methods of providing conductive heat transfer are used. 
Poželjno se koriste oba rješenja za osiguranje provodljivog prijenosa topline.
The method according to claim 2, wherein the d-methadone in the form of a pharmaceutically acceptable salt. 
D-metadon za uporabu prema zahtjevu 1, naznačen time što je d-metadon u obliku farmaceutski prihvatljive soli.
an additional active agent; or 
(a) dodatno aktivno sredstvo; ili
The benefits of the present invention are most pronounced in case the slurry is removed from the fermented liquid by means of kieselguhr filtration or membrane filtration. 
Postupak prema Zahtjevu 1, gdje se kaša koja sadrži PVPP čestice 1 kvasac uklanja iz fermentirane tekućine kieselguhr filtracijom ili membranskom filtracijom.
In one embodiment of the present invention there is provided a vaccine as herein described for use in a medicament for the treatment or prevention of diseases caused by infection by poliovirus and optionally Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae, Hepatitis B virus, Haemophilus influenzae, Neisseria meningitidis type A, Neisseria meningitidis type C, Neisseria meningitidis type W, Neisseria meningitidis type Y, Salmonella typhi or Hepatitis A. 
(iv) antigen virusa hepatitisa A, gdje je svaka komponenta izborno apsorbirana na aluminijev hidroksid ili aluminijev fosfat ili na smjesu obojeg; ili gdje je komponenta i), ii) ili iii) izborno ncapsorbirana na adjuvans. Upotreba cjepiva u skladu s patentnim zahtjevima 1-8, naznačena time što je navedeno cjepivo namijenjeno proizvodnji medikamenta za sprječavanje bolesti koju uzrokuje poliovirus, te bakterije Clostridium tetani, Corynebacterium diphtheriae i Bordetella pertussis.
The GLYX peptide for use according to any one of claims 4 or 5, wherein the patient is substantially relieved of at least one symptom within about 12 hours to about 1 day after administration of the GLYX peptide. 
Primjena GLYX-13 u proizvodnji medikamenata za terapiju refraktorne depresije u terapiji rezistentnih pacijenata kojima je terapija potrebna, naznačeno time da GLYX- 13, administriran takvom pacijentu, dovodi do značajnog ublažavanja najmanje jednog simptoma tokom 14 dana.
The acyl group can comprise a hydrocarbon which may be branched, unbranched, saturated or unsaturated. 
Acilna skupina može sadržavati ugljikovodik koji može biti razgranat, nerazgranat, zasićen ili nezasićen.
An oral formulation in tablet form of 9-[(2,2-dimethyl-propyl amino) methyl]-minocycline or a salt thereof, comprising 18 to 22% weight percent of the 9-[2,2-dimethyl-propyl amino) methyl]-minocycline, and wherein the tablet is formed by a roller compaction method. 
HR P20180836 T1 PATENTNI ZAHTJEVI Oralna formulacija u obliku tablete 9-[(2,2-dimetilpropilamino)metiljminociklina ili njegove soli, naznačena time što sadrži 18 do 22%, težinski, 9-[2,2-dimetilpropilamino)metillminociklina, te što je tableta oblikovana postupkom kompaktiranja valjkom.
The compound, or a pharmaceutically acceptable salt thereof, of claim 1, having the structure of Formula (Ib), wherein, 
Spoj ili njegova farmaceutski prihvatljiva sol u skladu s patentnim zahtjevom 1, naznačen time, da ima strukturu Formule (Ib), [image] naznačen time, da
In one embodiment, the modulator of a chloride transporter is thus an inhibitor of NKCC, preferably of NKCC1. 
Spoj za uporabu u skladu s patentnim zahtjevom 1, naznačeno time što navedeni spoj je inhibitor NKCC1.
The pharmaceutical composition for use according to any one of claims 1 to 4, wherein the composition comprises 10-10,000 µg/mL of PRG4. 
Farmaceutski oblik za uporabu prema zahtjevu 1 ili 2, gdje farmaceutski oblik sadrži PRG4 u terapijski učinkovitoj koncentraciji od 10-10,000 ug/mL.
Step (i): reacting 4-hydroxy piperidine of formula (1) with cyclobutanone of formula (2) in presence of sodium triacetoxy borohydride in ethylene dichloride at a temperature in the range of 20 °C to 30 °C for a period of 12 hours to 14 hours to obtain 1-cyclobutylpiperidin-4-ol of formula (3); 
: d 1) (2) u prisutnosti natrij triacetoksi borohidrida u etilen dikloridu pri temperaturi u rasponu do 20 *€ do 30 "€ u trajanju od 12 sati do 14 sati da bi se dobio 1-ciklobutilpiperidin-4-ol iz formule (3);
In addition, this study has shown that there was no trend or statistically significant drug effect on the ARCI 49. 
Dodatno je ova studija pokazala da nije bilo trenda ili statistički značajnog učinka lijeka na ARCI 49.
Silicified microcrystalline cellulose mg Microcrystalline cellulose 
Mikrokristalinična celuloza sa silicijem 34,50 mg Mikrokristalinična celuloza
The antibody of claim 5, wherein the antibody comprises the variable heavy chain of SEQ ID NO: 19 and the variable light chain of SEQ ID NO: 20. 
antitijelom koje ima teški lanac kao što je prikazano u SEK ID BR: 19 i laki lanac kao što je prikazano u SEK ID BR: 20;
the weight ratio of all of said aliphatic carboxylic acid salt(s) provided in step (c): all of said aliphatic carboxylic acid(s) provided in step (b) is from 51:49 to 75:25; 
- < težinski omjer svih navedenih soli alifatskih karboksilnih kiselina pripremljenih u koraku (c) prema svim navedenim alifatskim karboksilnim kiselinama pripremljenim u koraku (b) je od 51:49 do 75:25;
Aspect 7. The antibody of aspect 1-3, wherein said light chain variable region comprises the amino acid sequence. 
Protutijela sukladno patentnom zahtjevu 1, naznačeno time, da navedena varijabilna regija lakog lanca sadrži aminokiselinsku sekvencu.
The method according to claim 7, wherein the at least one hydrophilic gelling agent is selected from at least one of glucose, modified starch, methyl cellulose, carboxymethyl cellulose, propyl cellulose, hydroxypropyl cellulose, a carbomer polymer, alginic acid, sodium alginate, potassium alginate, ammonium alginate, calcium alginate, agar, carrageenan, locust bean gum, pectin and gelatin. 
Kompozicija za primjenu prema patentnom zahtjevu 1 ili 2, koja dalje sadrži najmanje jedan hidrofilni agens za geliranje odabran od glukoze, modificiranog škroba, metil celuloze, karboksimetil celuloze, propil celuloze, hidroksipropil celuloze, karbopol (RTM) polimera, alginske kiseline, natrij alginata, kalij alginata, amonij alginata, kalcij alginata, agara, karagenana, karuba gume, pektina, i želatina.
at least one viscosity-increasing agent, which, with the assistance of a necessary minimum quantity of an aqueous liquid, forms a gel with the extract obtained from the dosage form, which gel optionally remains visually distinguishable when introduced into a further quantity of an aqueous liquid, 
(b) barem jedno sredstvo za povećanje viskoziteta, koje tvori gel u ekstraktu dobivenom iz oblika davanja pomoću potrebne najmanje količine vodene tekućine, koji gel prvenstveno kod unošenja u daljnju količinu vodene tekućine ostaje vizualno razlikovnim,
The method according to claim 8, wherein the crystals of dimethyl fumarate are sieved or milled such that 90% of the particles have a particle size in the range of 5 - 1000 µm. 
Postupak prema zahtjevu 8, naznačen time, da se kristali dimetilfumarata prosijavaju ili melju tako, da 90 % od čestica imaju veličinu jedne čestice u rasponu od 5 do 1000 um.
A method as claimed in any of Claims 14 to 19, wherein the pH of the inner coating preparation is adjusted to be from about pH 7.5 to about pH 10, preferably from about pH 7.5 to about pH 8.5, more preferably about pH 8. 
Postupak sukladno patentnim zahtjevima 11 do 13, naznačeno time, da je pH unutarnjeg pripravka za oblaganje podešen da bude od pH 7,5 do pH 10, poželjno od pH 7,5 do pH 8,5, poželjnije oko pH 8.
In the embodiment shown, the receiver is housed in a plastic container. 
U prikazanoj izvedbi, prijemnik je smješten u plastično kućište.
The marking device according to claim 1, wherein the perforated sheet is made of a metal material. 
Uređaj sukladno zahtjevu 1, gdje je perforirani list izrađen od metalnog materijala.
wherein each different polypeptide is for simultaneous, separate or sequential use in the prevention or treatment of dust mite allergy by tolerisation. 
Sastav za uporabu u prevenciji ili liječenju alergije na grinje iz kućne prašine po toleranciji, naznačen time, što sadrži:
The reaction was stirred at room temperature for 23 hours then was quenched by adding 11.5µL acetic acid and 4µL water and stirring for one hour. 
Rcakcijska smjesa je bila miješana na sobnoj tempcraturi 23 sata 1 tada je bila zaustavljena dodavanjem 11.5 uL octene kiseline i 4 uL vode i miješana jedan sat.
An oligonucleotide according to claim 1, wherein the nucleotide analogue has a modified base and/or a non-natural internucleoside linkage, or a combination of these modifications. 
Oligonukleotid u skladu s patentnim zahtjevom 1, naznačen time što nukleotidni analog ima modificiranu bazu i/ili neprirodnu internukleozidnu vezu, ili kombinaciju tih modifikacija.
The polymorph of 6-(Piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride as claimed in claim 1, which is polymorph 2 and has at least reflection in an X-ray powder diffractogram using CuKa1 radiation at, 15.8 and 16.5 degrees 2theta ± 0.2 degrees 2theta. 
Polimorf 6-(piperidin-4-iloksi)-2H-izokinolin-1-on hidroklorida prema zahtjevu 1, naznačen time da je polimorf 2 i ima refleksiju u difraktogramu X-zraka na prahu korištenjem CuKa, zračenja barem kod 8.1, 15.8 i 16.5 stupnjeva 2theta + 0.2 stupnjeva 2theta.
A pharmaceutical comprising the 1-thio-D-glucitol compound, the pharmaceutically acceptable salt thereof, or the hydrate of the compound or the salt according to claim 1, in combination with at least one pharmaceutical selected from the group consisting of a hydroxymethylglutaryl-CoA reductase inhibitor, a fibrate compound, a squalene synthase inhibitor, an acyl-CoA:cholesterol acyltransferase inhibitor, a low density lipoprotein receptor accelerator, a microsome triglyceride transfer protein inhibitor, and an anorectic. 
Farmaceutski pripravak prema zahtjevu 21, naznačen time da nadalje sadrži inhibitor hidroksimetilglutaril-CoA reduktaze, spoj fibrata, inhibitor sintaze skvalena, inhibitor acil-CoA kolesterol aciltransferaze, akcelerator receptora lipoproteina niske gustoće, inhibitor transfer proteina mikrosomnih triglicerida, te anorektik. Postupak dobivanja 1-tio-D-glucitol spoja prema slijedećoj formuli I, ili njegovo farmaccutski prihvatljive soli, ili hidrata spoja ili njegove soli:
A composition according to Claim 1, in which the S-adenosyl methionine sulphate paratoluene sulphonate or S-adenosyl methionine-1,4-butane disulphonate is present in a quantity varying from 30 to 90% by weight with respect to the weight of the composition, preferably from 50 to 85% by weight with respect to the weight of the composition. 
Pripravak u skladu s patentnim zahtjevom 1, naznačen time što je S-adenozilmetionin-sulfat-para-toluensulfonat ili S-adenozilmetionin-1,4-butan-disulfonat u njemu prisutan u količini koja se kreće od 30 do 90%, težinski, u odnosu na težinu pripravka, po mogućnosti od 50 do 85%, težinski, u odnosu na težinu pripravka.
at least 80% (preferably 90%) of the polypeptides retain their binding activity to RANKL after storage at 37±5°C up to at least 2 weeks (preferably at least 4 weeks, more preferably at least 6 weeks, most preferably at least 8 weeks or more) compared to the binding activity prior to storage, said binding activity as measured by ELISA and/or Biacore; and/or 
manje od 10% polipeptida tvori dimere tijekom skladištenja na temperaturi od 37±5°C do najmanje 2 tjedna (poželjno najmanje 3 tjedna, najmanje 5 tjedana, najmanje 8 tjedana, najmanje 10 tjedana, najmanje 3 mjeseca, najmanje 6 mjeseci, najmanje 1 godinu, 1.5 godinu ili čak 2 godine ili više), te se % dimera mjeri pomoću SE-HPLC;
The cuff 6 is adjustable in height thanks to the presence of a small tongue 35 which may be selectively made to protrude from the rear area of the upper perimetral edge 58 of the cuff itself; the tongue 35 is connectable to the cuff 6, in a desired vertical position, by means of the insertion of a third screw 36 in a sixth hole 37 provided on the cuff 6 in proximity to the upper perimetral edge 58, and therefore in one of two or more sixth holes 38 provided longitudinally to the tongue 35 itself. 
Manžeti 6 se može podesiti visina zahvaljujući prisutnosti malog jezika 35 koji se može izraditi selektivno, tako da strši od stražnjeg područja gornjeg obodnog ruba 58 same manžete, pri čemu se taj jezik 35 može spojiti s manžetom 6 u željenom okomitom položaju umetanjem trećeg vijka 36 u šeste rupice 37 načinjene na manžeti 6 u blizini gornjeg obodnog ruba 58, a zbog toga u jednu od dvije ili više šestih rupica 38 načinjenih uzdužno sa samim jezikom 35.
wherein X is Cl and wherein the agomelatine hydrochloride hydrate is in a crystalline form having the following X-ray powder diffraction diagram expressed in terms of Bragg 2θ angle, interplanar spacing d and relative intensity: 2-Theta 
Agomelatin hidroklorid hidrat formule I u skladu s patentnim zahtjevom 1, u kristalnom obliku, naznačen time, da su Braggov kut 20, interplanarni razmak D i relativni intenzitet kako slijedi: 2-Theta
A molecule according to claim 1, wherein the polyethylene glycol molecule has a molecular weight of about 0.5 kD to about 30 kD. 
Molekula koja sadrži fragment Fab protutijela u skladu s patentnim zahtjevom 1, naznačena time što molekula polietilen-glikola ima molekulsku težinu od 20 kDa.
A method of treating opioid toxicity or overdose in a subject in need thereof comprising administrating L-malate salt of Compound-1 having the formula: 
Spoj od formule: radi uporabe u postupku za nekontrolirano liječenje opioidne toksičnosti ili predoziranja opioidom kod pacijenta kojem je nužno.
% Decrease of plasma glucose in STZ diabetic rats at 5 hr after an oral dose of 0.1 mg/kg vs. vehicle treated controls 
roj spoja Protokol Osobina % smanjenje glukoze u plazmi kod STZ dijabetičnih štakora 5 sati poslije oralne!
A mix of agonist (10 nM Prostaglandin D2) and 5 µM forskolin is prepared in assay stimulation buffer and added to the assay plate (5 µL/well). 
Smjesa agonista (10 nM prostaglandin D>) i 5 uM forskolina je pripravljena u pokusnom puferu za stimulaciju i dodana je u pokusnu pločicu (5 ul/jamici).
The compound of claim 1 or 2 for use in the treatment or prevention of bacterial infections or disorders associated with bacterial infections in an animal. 
Spoj u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju bakterijskih infekcija 1li poremećaja povezanih s bakterijskim infekcijama kod životinje.
a refrigerated space 21 for containing the bags, in which there is a magazine 3 comprising a plurality of cells 31, each capable of containing a single bag, each of the cells 31 being identified by a cell code; 
- - prostor koji se hladi 21, koji sadržava vrećice, i u kojemu se nalazi veći broj ćelija 31, od kojih svaka ćelija može sadržavati samo jednu vrećicu, i pri čemu je svaka ćelija 31 označena kodom ćelije;
Both the antagonistic activity test on cells transfected with the human receptor and the in vivo test are highly predictive of the expected dose for therapeutical applications in humans. 
Test antagonističke aktivnosti na stanicama transificiranim humanim receptorom i in vivo test su vrlo prediktabilni za očekivanu dozu za terapijsko primjenu kod ljudi. KRATICE IT
is selected from the group consisting of B-Ala, Arg, DArg, Gly, Lys, Lys(iPr), and Om, or is absent; 
se bira iz skupine koju čine B-Ala, Arg, dArg, Gly, Lys, Lys(iPr), te Orn, ili je odsutan;
The blast-resistant container according to claim 5, wherein the rods (15) are straight and are aligned perpendicularly with respect to the ribs (14). 
Kontejner otporan na eksplozije iz zahtjeva 3, pri čemu su šipke (15) ravne 1 postavljene okomito u odnosu na rebra
The process according to claim 1, wherein in the step (3), the crystals are precipitated in the presence of a-crystals of the reaction product as a seed. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da se u koraku (3) kristali talože u nazočnosti a-kristala produkta reakcije kao sjeme.
Suitably, at least one R5 group is fluoro, which at least one fluoro is preferably positioned at an ortho-(2-) position on the benzene ring. 
Poželjno je barem jedna R? skupina fluoro, pri čemu je najmanje jedan fluoro poželjno smješten na orto-(2-) položaju benzenskog prstena.
The process of claim 18, wherein the temperature profile during the curing step c) shows a plateau-like form and wherein said temperature is at least about 68° C. and the curing time is in the range of from about 1 minute to about 2 hours. 
Postupak prema zahtjevu 18, naznačen time da temperaturni profil u toku koraka stvrdnjavanja pokazuje oblik platoa i gdje je navedena temperatura barem oko 68 "C i gdje je vrijeme stvrdnjavanja poželjno u rasponu od oko 1 minute do oko 2 sata.
the first fragment is a toxin A repeating domain fragment; the second fragment is a toxin B repeating domain fragment; 
(li) drugi fragment je fragment ponavljane domene toksina B i sadrži najmanje 100 aminokiselina;
AA9 is L-phenylalanine; or ii) the cyclic peptide comprises formula IIb or a pharmaceutically acceptable salt thereof and 
A? je L-fenilalanin; ili ii) ciklični peptid sadrži formulu IIb, ili njegova farmaceutski prihvatljiva sol; i AA! je L-fenilalanin AA? je D-fenilalanin;
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropidin. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) klorotalonil.
having powder X-ray diffraction with CuKa1 radiation spectra having peaks at about 16.9, 8.1, 19.1, 20.8, 21.3, 22.0, 22.8, 23.8, 24.9, 25.0, 29.1, 29.8, 34.2 and 35.8 + 0.2 degrees 2 theta, characterized in that the compound A is at least 75% free from other solid forms of Compound A. 
s rendgenskom difrakcijom praha sa spektrom zračenja CuKa1, koja ima vršne vrijednosti na približno 16,9, 18,1, 19,1, 20,8, 21,3, 22,0, 22,8, 23,8, 24,9, 25,0, 29,1, 29,8, 34,2 i 35,8 + 0,2 stupnjeva 2-theta, naznačen time, da je spoj A najmanje 75% bez ostalih krutih tvorbi spoja A.
A connexin-blocking agent for use to treat cognitive disorders by potentiating the effect of an acetylcholinesterase inhibitor (AChEI) or a pharmaceutical salt thereof, wherein said acetylcholinesterase inhibitor is: 
Sredstvo koje blokira koneksin za upotrebu u liječenju kognitivnih poremećaja potenciranjem učinka donepezila ili njegove farmaceutske soli.
The process according to claim 6, wherein the active ingredient is a corticosteroid selected from the group consisting of budesonide, fluticasone propionate, fluticasone furoate, mometasone furoate, beclomethasone dipropionate and ciclesonide. 
Postupak prema patentnom zahtjevu 6, naznačeno time da je aktivni sastojak kortikosteroid odabran iz skupine koju čine budezonid, flutikason-propionat, flutikason-furoat, mometazon-furoat, beklometazon-dipropionat i ciklezonid.
one or more syringes, 
- jednu ili više šprica,
wherein represents any structure of the following formula group [4′]: 
Z' predstavlja bilo koja struktura prema slijedećoj skupini formula [4']:
or an amide, an ester or a salt of the polypeptide. 
V; ili amid, ester ili sol polipetida.
a form-metrics block, receiving the output of the first and second de-interleavers and forming metric information for decoding. 
oblikovani metrički blok koji prima izlaz iz prvih i drugih prepletala i formira metričke informacije za dekodiranje.
Fig. 78 shows only addresses of the first 24 symbols. 
(32) Datum podnošenja prve prijave: 18.02.2009.
The compound of Paragraph 1, wherein R5 is represented by the following formula: wherein: 
Spoj prema zahtjevu 1, pri čemu je Rsprikazan slijedećom formulom: Rome
The enantiomers A, B, C and D may each be presented in a substantially enantiomerically pure form or as mixtures with other enantiomers of the invention. 
Izomer A može biti prisutan u potpuno enantiomerno čistom obliku ili kao smjesa s ostalim enantiomerima 3,11b-cis- dihidrotetrabenazina koji su ovdje opisani.
the winder spools (4, 5) are arranged in side by side arrangement and a respective guide wheel or pulley (8, 9) is positioned outwardly of each respective winder spool (4, 5); and/or 
Jedinica za namatanje, namijenjena upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što se kalemi za namatanje nalaze u bok-uz-bok položaju, a odgovarajuće kolo ili kolut za vođenje (8, 9) se nalazi prema van u odnosu na odgovarajuće kaleme za namatanje (4, 5).
The invention provides a process for preparing an influenza vaccine from influenza virus that has been grown in a culture of a Vero cell line, as defined in the claims. 
Postupak priprave antigena cjepiva u kulturi Vero stanične linije, koji sadrži korak testiranja na patogen izabran iz skupine koja sadrži parvovirus, JC poliomavirus 1 cirkovirus.
To prepare slides, the cells were collected by centrifugation and resuspended in fresh fixative. 
), zatvoren i čuvan preko noći ili duže na približno 2-8*C. Za pripremu pločica, stanice su sakupljene centrifugiranjem i reasuspendirane u svježem fiksativu.
The water phase was further extracted with ethyl acetate (2×100 mL) and the combined organic phases were washed with brine and dried over MgSO4 and evaporated in vacuo to a dark orange oil which crystallized upon standing. 
Vodena faza je dalje ekstrahirana etil acetatom (2x100 mL), a kombinirane organske faze oprane s u rasolu i osušene s MgSO, te evaporirane in vacuo do tamno narančastog ulja koje se nakon stajanja kristaliziralo.
The liquefied gas treatment system according to claim 1, further comprising decompressing means configured to decompress the BOG liquefied by the heat exchanger. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što je element za dekomprimiranje ekspanzijski ventil (22) ili ekspander (52).
a mutation in the gene encoding lipoxygenase 1, causing a total loss of lipoxygenase 1 activity. 
Biljka ječma ili njezin dio sukladno bilo kojem od zahtjeva 6 to 9, pri čemu biljka ječma nosi mutaciju genetskog koda lipoksigenaze 1, uzrokujući poptpun gubitak aktivnosti lipogenaze 1.
Addition of the antibiotic solutions: 
Broj objave europskog patenta:
The system of claim 1 wherein the biologically active or chemical substance comprises at least in part, living organisms. 
Sustav prema zahtjevu 1, naznačen time što se biološki aktivna ili kemijska supstanca sastoji bar dijelom od živih organizama.
The panel according to any claims 1 to 12 characterized in that sheet of metal of cover (5) is not penetrated but adapted which provides for water- and air-tightness and at the same time necessary load carrying capacity of fastener of decorative slats (13). 
Panel prema bilo kojem od zahtjeva 1 do 12, naznačen time što se ne prodire kroz metalni lim pokrivača (5), već se on prilagođava, čime se omogućava nepropusnost za vodu i za zrak 1 u isto vreme neophodna nosivost samog nosača dekorativnih letvi (13).